StartUp / Biotech
Revolutionizing Glioblastoma Treatment with SOMA-1
SOMA-1 is a brain implant developed by Coherence Neuro to monitor and treat glioblastoma, an aggressive brain cancer. This device aims to provide real-time monitoring and electrical stimulation to disrupt tumor growth, addressing the limitations of current treatment options.
Source material: Can This Tiny Brain Implant Increase Cancer Survival?
Summary
SOMA-1 is a brain implant developed by Coherence Neuro to monitor and treat glioblastoma, an aggressive brain cancer. This device aims to provide real-time monitoring and electrical stimulation to disrupt tumor growth, addressing the limitations of current treatment options.
Glioblastoma has a poor prognosis, with an average survival time of about 14 months. Current treatments primarily involve surgery, radiotherapy, and a single drug that is effective for only half of patients, leaving many in uncertainty between MRI scans.
The founders of Coherence Neuro express frustration over the slow progress in glioblastoma treatment advancements. They emphasize the emotional toll on patients and families who feel trapped by outdated methods and are eager for innovative solutions.
SOMA-1 is designed to be implanted during standard tumor removal surgery, allowing for continuous monitoring of tumor growth through electrical signals. This approach aims to provide timely interventions and improve patient outcomes.
Perspectives
short
Proponents of SOMA-1
- Claims SOMA-1 can provide real-time monitoring and treatment for glioblastoma, improving patient outcomes
- Highlights the urgent need for innovative cancer treatments as current options are inadequate
Skeptics of SOMA-1
- Questions the effectiveness of electrical stimulation in disrupting glioblastoma growth due to tumor heterogeneity
- Raises concerns about the integration of electrical signals with brain activity and individual patient responses
Neutral / Shared
- Notes that glioblastoma has a poor prognosis and limited treatment options
- Acknowledges the need for continuous monitoring of tumor growth post-surgery
Metrics
other
about 14 months
average survival time for glioblastoma patients
This statistic highlights the urgency for innovative treatments
the average survival time for someone diagnosed with Gleoblastoma is about 14 months.
other
more than 13,000 Americans every year cases
annual incidence of glioblastoma in the US
This underscores the widespread impact of glioblastoma
It is a word that throws fear into more than 13,000 Americans every year.
Key entities
Timeline highlights
00:00–05:00
SOMA-1 is a brain implant designed to monitor and treat glioblastoma, an aggressive brain cancer, through real-time electrical stimulation. The technology aims to improve patient outcomes by providing timely interventions compared to traditional MRI monitoring.
- SOMA-1 is a brain implant aimed at treating glioblastoma, an aggressive brain cancer with an average survival time of about 14 months, by providing real-time monitoring and electrical stimulation
- Current glioblastoma treatments are limited to surgery, radiotherapy, and a single drug that works for only half of patients, leaving many in uncertainty between MRI scans
- The founders of Coherence Neuro are frustrated with the slow progress in glioblastoma treatment advancements, emphasizing the emotional impact on patients and their families who feel trapped by outdated methods
- Glioblastomas unique growth pattern, which infiltrates the brain rather than forming a distinct mass, complicates surgical removal and effective monitoring
- There is an urgent need for innovative monitoring technologies and treatment options to enhance outcomes for glioblastoma patients, as existing practices are considered inadequate
05:00–10:00
Coherence Neuro is developing SOMA-1, a brain implant designed to monitor and treat glioblastoma through real-time electrical stimulation. The device aims to improve patient outcomes by providing timely interventions during standard tumor removal surgery.
- SOMA-1 is a brain implant designed for real-time monitoring and targeted electrical stimulation during standard tumor removal surgery, aimed at treating glioblastoma
- Current monitoring methods, like MRIs, are inadequate for tracking glioblastomas aggressive nature, which has an average survival time of about 14 months
- The device incorporates multiple electrodes to listen to brain activity and deliver stimulation, potentially extending life expectancy by disrupting cancer cell division
- Co-founder Elise Jenkins highlights the need for a modular device that adapts to various tumor locations, showcasing Coherence Neuros innovative approach to developing a data platform that learns from real-time neural signals
- The urgent demand for this technology is reflected in the overwhelming interest from clinicians and patients seeking advancements in cancer treatment and monitoring
10:00–15:00
Coherence Neuro is developing SOMA-1, a brain implant designed to monitor glioblastoma and deliver electrical stimulation in real time. This technology aims to improve patient outcomes by providing continuous monitoring and timely interventions during standard tumor removal surgery.
- Residual cancer cells post-surgery can regrow aggressively, underscoring the necessity for continuous monitoring
- The FDA-approved Optune device has shown that electrical fields can slow glioblastoma growth, but its effectiveness requires consistent use for 22-24 hours daily
- SOMA-1 aims to provide real-time tumor growth monitoring through electrical signals, presenting a more dynamic alternative to traditional MRI scans
- Coherences research utilizes mouse models to assess glioblastoma by measuring tumor growth through electrical activity instead of relying solely on static imaging
- The companys innovative approach to monitoring cancer as an electrical system may extend beyond glioblastoma, potentially transforming treatment for various cancer types
15:00–20:00
Coherence Neuro is developing SOMA-1, a brain implant designed to monitor glioblastoma and deliver electrical stimulation in real time. The technology aims to improve patient outcomes by providing timely interventions during standard tumor removal surgery.
- The SOMA-1 implant by Coherence Neuro is designed for placement in the skull during tumor removal surgery, enabling real-time monitoring of glioblastoma and delivering targeted electrical stimulation to inhibit tumor growth
- SOMA-1s materials do not interfere with MRI imaging, addressing limitations of traditional scans that can miss tumors due to artifacts from metal implants
- The founders stress the urgent need for SOMA-1, as current cancer treatments often leave patients with limited options and a poor prognosis, aiming to shift cancer from a terminal diagnosis to a manageable condition
- Coherence Neuro plans to start long-term clinical trials in Australia within two years, with the goal of making SOMA-1 available globally within a decade, depending on successful safety and efficacy results
- The motivation behind SOMA-1 stems from the urgent requests from patients and clinicians for innovative cancer treatments, highlighting the challenge of balancing rapid development with patient safety